Acute pancreatitis (AP) is characterized by inflammation of the exocrine pancreas which occurs as a result of autodigestion of the pancreas by pancreatic enzymes. AP is associated with acinar cell injury and both a local and systemic inflammatory response. The incidence of acute pancreatitis has been increasing worldwide, but the major etiologies remain gallstones and alcohol. According to The National Pancreas Foundation, acute pancreatitis is an inflammatory condition of the pancreas that is painful and deadly. Despite the great advances in critical care medicine over the past 20 years, acute pancreatitis’ mortality rate has remained at about 10%.
Diagnosis of pancreatic problems is often difficult, and treatments are delayed because the organ is relatively inaccessible. There are no easy ways to see the pancreas directly without surgery, and available imaging studies are often inadequate. In addition to the acute form, there are hereditary and chronic forms of pancreatitis that can devastate a person over many years. Sufferers often endure pain and malnutrition and are most likely left with a higher risk of pancreatic cancer.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/acute-pancreatitis-market
The Acute Pancreatitis Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Acute Pancreatitis market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Acute Pancreatitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Acute Pancreatitis Market Key Facts
According to Delveinsight’s estimates, the total diagnosed incident population of Acute Pancreatitis in the 7MM was 502,390 in 2020.
The estimates suggest that the gender-based incidence varied in the 7MM with the male incident cases higher in the United Kingdom, Japan, and Germany, whereas in the United States the female incident cases were higher.
In approximately 15% of cases, patients can develop severe pancreatitis with tissue damage (also called Acute Necrotizing Pancreatitis (ANP)).
As per a study by Vege et al., the reported annual incidence of acute pancreatitis in the United States ranges from 4.9 to 35 per 100,000 population.
According to a study published by Ouyang et al., 2017, the incidence of acute pancreatitis ranges from 13 to 45 per 100,000 population-years and that of chronic pancreatitis ranges from 5 to 12 per 100,000 population-years.
Key Benefits of Acute Pancreatitis Market Report
Acute Pancreatitis market report provides an in-depth analysis of Acute Pancreatitis Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
The report will help in developing business strategies by understanding the Acute Pancreatitis Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
The market report covers Acute Pancreatitis current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
The report provides a detailed assessment of the Acute Pancreatitis market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
The current understanding of Acute Pancreatitis has greatly improved in recent decades, leading to growing awareness, improved management, and better outcomes.
The market size of Acute Pancreatitis is anticipated to increase during the study period owing to the launch of upcoming therapies, changing lifestyles, increasing disposable income, etc. The increasing awareness of the disease and rising incidence of Acute Pancreatitis will also fuel the market growth.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Acute Pancreatitis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Acute Pancreatitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Acute Pancreatitis Therapeutics Market
The management of acute pancreatitis depends on the severity of the disease and the concomitant complications. Treatment for acute pancreatitis aims to help control the condition and manage any symptoms. This usually involves admission to the hospital. One may be given fluids directly into a vein (intravenous fluids), pain relief, liquid food through a tube in the stomach, and oxygen through tubes in the nose.
Currently, the effective management of Acute Pancreatitis mainly involves the usage of symptomatic and supportive therapies including Pain Medications, Nutritional Support, Hydration Therapy, Pancreatic Enzymes such as Somatostatin, and antibiotics. There are no approved therapies in the market for the treatment of Acute Pancreatitis at present, thereby leading to a largely untapped market in the offering for major players to capitalize on.
Acute Pancreatitis Epidemiology
The epidemiology section covers insights about the historical and current Acute Pancreatitis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Acute Pancreatitis Epidemiology Segmentation
Diagnosed Incident Cases of Acute Pancreatitis
Diagnosed Incidence of Acute Pancreatitis by Etiology
Diagnosed Incidence of Acute Pancreatitis by Severity
Diagnosed Incidence of Acute Pancreatitis by Gender
Acute Pancreatitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Pancreatitis market or expected to get launched in the market during the study period. The analysis covers Acute Pancreatitis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Acute Pancreatitis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Acute Pancreatitis market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Acute Pancreatitis emerging therapies.
The dynamics of the acute pancreatitis (AP) market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. Analysis of the Pipeline scenario reveals only one promising candidate under clinical development for Acute Pancreatitis which is expected to hit the market during the forecast period i.e. Auxora (CalciMedica, Inc.).
Since no therapy is approved for the treatment of acute pancreatitis and the presence of a highly untapped market, Auxora could be a major player and have a major market share if and once approved. The current research pipeline of AP therapy is weak, which is one of the factors that will affect the emerging AP market. Overall, the rising incidence of the disease along with the approval of emerging therapy will fuel the Acute Pancreatitis market during the forecasted period.
Table of Content
1. Key Insights
2. Executive Summary
3. Acute Pancreatitis Competitive Intelligence Analysis
4. Acute Pancreatitis Market Overview at a Glance
5. Acute Pancreatitis Disease Background and Overview
6. Acute Pancreatitis Patient Journey
7. Acute Pancreatitis Epidemiology and Patient Population
8. Acute Pancreatitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Pancreatitis Unmet Needs
10. Key Endpoints of Acute Pancreatitis Treatment
11. Acute Pancreatitis Marketed Products
12. Acute Pancreatitis Emerging Therapies
13. Acute Pancreatitis Seven Major Market Analysis
14. Attribute Analysis
15. Acute Pancreatitis Market Outlook (7 major markets)
16. Acute Pancreatitis Access and Reimbursement Overview
17. KOL Views on the Acute Pancreatitis Market.
18. Acute Pancreatitis Market Drivers
19. Acute Pancreatitis Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/acute-pancreatitis-market
Spinal Stenosis Devices Market Share
As per the Delveinsight, the stabilization system captured the maximum Spinal Stenosis Devices market share of spinal stenosis across 7MM, followed by interspinous spacers in the year 2020. The leading companies in the Spinal Stenosis Devices market include Boston Scientific, NuVasive, Medtronic, Zimmer Biomet, Surgalign, Orthofix International NV, Stryker, Johnson & Johnson, NuVasive, and many others. DelveInsight has analyzed the Spinal Stenosis Devices market and covered the key aspects guiding the market growth. For more detailed information, visit: Spinal Stenosis Devices Market Share
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States